Efficacy of adjuvant XELOX and FOLFOX6 chemotherapy after D2 dissection for gastric cancer

Table 3 Grade 3/4 adverse reactions in 5-fluorouracil, folinic acid and oxaliplatin and capecitabine and oxaliplatin treatment groups n (%)

Adverse reactions	FOLFOX6	XELOX	P value
	(n = 48)	(n = 214)
At least one adverse event	19 (39.6)	75 (35)	0.618
Vomitting	5 (10.4)	16 (7.5)	0.555
Anorexia	5 (10.4)	20 (9.3)	0.788
Oral mucositis	1 (2.0)	3 (1.4)	0.557
Diarrhea	4 (8.3)	14 (6.5)	0.751
Hand-foot syndrome	0 (0.0)	21 (9.8)	0.018
Peripheral neurotoxicity	9 (18.8)	25 (11.7)	0.232
Leukocyte/neutropenia	7 (14.5)	16 (7.5)	0.153
Thrombocytopenia	4 (8.3)	14 (6.5)	0.751
ALT/AST increase	1 (2.0)	5 (2.3)	0.999

AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; FOLFOX6: 5-fluorouracil, folinic acid and oxaliplatin; XELOX: Capecitabine and oxaliplatin.